keyword
MENU ▼
Read by QxMD icon Read
search

Gastroesophagic junction cancer

keyword
https://www.readbyqxmd.com/read/27923357/patient-preferences-for-palliative-treatment-of-locally-advanced-or-metastatic-gastric-cancer-and-adenocarcinoma-of-the-gastroesophageal-junction-a-choice-based-conjoint-analysis-study-from-germany
#1
R Hofheinz, J Clouth, J Borchardt-Wagner, U Wagner, E Weidling, M H Jen, P Brück
BACKGROUND: Decisions on palliative chemotherapy (CT) for locally advanced or metastatic gastric cancer (mGC) require trade-offs between potential benefits and risks for patients. Healthcare providers and payers agree that patient-preferences should be considered. We conducted a choice-based conjoint (CBC) analysis study in pre-treated patients from Germany with mGC or locally advanced or metastatic adenocarcinoma of the gastroesophageal junction (mGEJ-Ca), to evaluate their preferences when hypothetically selecting a CT regimen...
December 6, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27811508/hospital-of-diagnosis-influences-the-probability-of-receiving-curative-treatment-for-esophageal-cancer
#2
Margreet van Putten, Marijn Koëter, Hanneke W M van Laarhoven, Valery E P P Lemmens, Peter D Siersema, Maarten C C M Hulshof, Rob H A Verhoeven, Grard A P Nieuwenhuijzen
OBJECTIVE: The aim of this article was to study the influence of hospital of diagnosis on the probability of receiving curative treatment and its impact on survival among patients with esophageal cancer (EC). BACKGROUND: Although EC surgery is centralized in the Netherlands, the disease is often diagnosed in hospitals that do not perform this procedure. METHODS: Patients with potentially curable esophageal or gastroesophageal junction tumors diagnosed between 2005 and 2013 who were potentially curable (cT1-3,X, any N, M0,X) were selected from the Netherlands Cancer Registry...
November 1, 2016: Annals of Surgery
https://www.readbyqxmd.com/read/27784452/-second-line-treatment-for-metastatic-or-locally-advanced-gastric-cancer
#3
K C Li, S Y Cheng, J Du, J Li
Gastric cancer is one of the major causes of cancer-related deaths. Many patients with metastatic gastric cancer after first-line chemotherapy received salvage chemotherapy in routine clinical practice. Recent phase Ⅲ trials demonstrated substantial prolongation of overall survival to support this chemotherapy or targeted therapy as a second-line treatment. Both ramucirumab monotherapy and ramucirumab plus paclitaxel were approved by FDA in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma...
October 23, 2016: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://www.readbyqxmd.com/read/27778127/race-is-a-risk-for-lymph-node-metastasis-in-patients-with-gastric-cancer
#4
Naruhiko Ikoma, Mariela Blum, Yi-Ju Chiang, Jeannelyn S Estrella, Sinchita Roy-Chowdhuri, Keith Fournier, Paul Mansfield, Jaffer Ajani, Brian D Badgwell
BACKGROUND: The frequency of lymph node metastasis in each T stage of gastric cancer has not been as well described for Western populations as it has for Asian populations. This study aimed to determine these frequencies and to investigate risk factors associated with lymph node metastases in a racially diverse U.S. POPULATION: HASH(0x4ea0398) METHODS: A prospectively maintained database of 8260 patients with gastric or gastroesophageal junction adenocarcinoma treated at our institution from 1995 to 2013 was reviewed to identify those who underwent surgical resection without preoperative therapy...
October 24, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27774774/positioning-of-second-line-treatment-for-advanced-gastric-and-gastroesophageal-junction-adenocarcinoma
#5
REVIEW
Carles Pericay, Fernando Rivera, Carlos Gomez-Martin, Inmaculada Nuñez, Alejo Cassinello, Esteban Rodrigo Imedio
Tumors of the upper gastrointestinal tract are increasing in incidence; yet, approaches to the treatment of advanced gastric and/or gastroesophageal junction cancer vary widely, with no internationally agreed first-line regimens. Recent clinical trials have shown that second-line treatment is now possible for selected patients with advanced disease, and current data suggest that the combination of ramucirumab plus paclitaxel may become a standard of care in the second-line setting for metastatic gastric cancer...
October 24, 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27765757/ramucirumab-combined-with-folfox-as-front-line-therapy-for-advanced-esophageal-gastroesophageal-junction-or-gastric-adenocarcinoma-a-randomized-double-blind-multicenter-phase-ii-trial
#6
H H Yoon, J C Bendell, F S Braiteh, I Firdaus, P A Philip, A L Cohn, N Lewis, D M Anderson, E Arrowsmith, J D Schwartz, L Gao, Y Hsu, Y Xu, D Ferry, S R Alberts, Z A Wainberg
BACKGROUND: We report the first randomized, Phase II trial of ramucirumab, an anti-vascular endothelial growth factor receptor-2 monoclonal antibody, as front-line therapy in patients with advanced adenocarcinoma of the esophagus or gastric/gastroesophageal junction (GEJ). PATIENTS AND METHODS: Patients from the USA with advanced esophageal, gastric, or GEJ adenocarcinoma randomly received (1:1) mFOLFOX6 plus ramucirumab (8 mg/kg) or mFOLFOX6 plus placebo every 2 weeks...
October 20, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27759620/trainee-involvement-in-ivor-lewis-esophagectomy-does-not-negatively-impact-outcomes
#7
Alexander W Phillips, Barry Dent, Maziar Navidi, Arul Immanuel, S Michael Griffin
OBJECTIVE: The aim of the present study was to determine whether trainee involvement in esophageal cancer resection is associated with adverse patient outcomes. BACKGROUND: Operative experience for surgical trainees is under threat. A number of factors have been implicated in this leading to fewer hours for training. Esophagogastric cancer training is particularly vulnerable due to the publication of individual surgeon results and a perception that dual consultant operating improves patient outcomes...
October 17, 2016: Annals of Surgery
https://www.readbyqxmd.com/read/27753660/assessment-of-egfr-and-erbb2-her2-in-gastric-and-gastroesophageal-carcinomas-egfr-amplification-is-associated-with-a-worse-prognosis-in-early-stage-and-well-to-moderately-differentiated-carcinoma
#8
Jia-Bin Liao, Huai-Pao Lee, Hsiao-Ting Fu, Herng-Sheng Lee
Epidermal growth factor receptor 1 (EGFR) and erb-b2 receptor tyrosine kinase 2 (ERBB2/HER2) are frequently dysregulated in human cancers. We analyzed EGFR and ERBB2 status in 105 gastric and gastroesophageal junction carcinoma and their clinicopathologic features. For EGFR, 92 (88%) tumors were scored as 0, 2 (2%) as 1+, 7 (7%) as 2+, and 4 (3%) as 3+ by immunohistochemistry (IHC) and 4 (4%) tumors showed EGFR amplification by fluorescence in situ hybridization (FISH). For ERBB2, 90 (86%) tumors were scored as 0, 4 (4%) as 1+, 6 (6%) as 2+, and 5 (5%) as 3+ by IHC and 12 (12%) showed ERBB2 amplification by FISH...
October 7, 2016: Applied Immunohistochemistry & Molecular Morphology: AIMM
https://www.readbyqxmd.com/read/27738344/pre-treatment-assay-of-5-fluorouracil-degradation-rate-5-fudr-to-improve-prediction-of-5-fluorouracil-toxicity-in-gastro-esophageal-cancer
#9
Marina Borro, Andrea Botticelli, Federica Mazzuca, Elisa Concetta Onesti, Giovanna Gentile, Adriana Romiti, Bruna Cerbelli, Eva Mazzotti, Luca Marchetti, Luana Lionetto, Maurizio Simmaco, Paolo Marchetti
BACKGROUND: 5-fluorouracil (5-FU) based chemotherapy is the most common first line regimen used in gastric and gastroesophageal junction cancer, but development of severe toxicity is a main concern in the treatment. The present study is aimed to evaluate a novel pre-treatment assay, known as the 5-FU degradation rate (5-FUDR), as a predictive factor for 5-FU toxicity. METHODS: Pre-treatment 5-FUDR and gene polymorphisms related to 5-FU metabolism (DPYDIVS14+1G>A, MTHFRA1298T or C677T, TMYS TSER) were characterized in gastro-esophageal cancer patients...
October 11, 2016: Oncotarget
https://www.readbyqxmd.com/read/27729298/final-results-of-nrg-oncology-rtog-0246-an%C3%A2-organ-preserving-selective-resection-strategy-in%C3%A2-esophageal-cancer-patients-treated-with-definitive%C3%A2-chemoradiation
#10
Stephen G Swisher, Jennifer Moughan, Ritsuko U Komaki, Jaffer A Ajani, Tsung T Wu, Wayne L Hofstetter, Andre A Konski, Christopher G Willett
INTRODUCTION: The impact of selective surgical resection for patients with esophageal cancer treated with definitive chemoradiation has not been clearly evaluated long-term. METHODS: NRG (National Surgical Adjuvant Breast and Bowel Project, Radiation Therapy Oncology Group, Gynecologic Oncology Group) Oncology Radiation Therapy Oncology Group 0246 was a multi-institutional, single-arm, open-label, nonrandomized phase II study that enrolled 43 patients from September 2003 to March 2008 with clinical stage T1-4N0-1M0 squamous cell or adenocarcinoma of the esophagus or gastroesophageal junction from 19 sites...
October 8, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27704661/isolated-local-recurrence-or-solitary-solid-organ-metastasis-after-esophagectomy-for-cancer-is-not-the-end-of-the-road
#11
L Depypere, T Lerut, J Moons, W Coosemans, G Decker, H Van Veer, P De Leyn, P Nafteux
Recurrent disease after esophagectomy bears an infaust prognosis, especially when multiple recurrences are present. But little is known about survival in patients with limited recurrence (solitary locoregional recurrence or solid organ metastasis). Herein, we report our experience with these subgroups. We analyzed 1754 consecutive patients surgically treated with curative resection for esophageal cancer and cancer of the gastroesophageal junction between 1990 and 2012. Seven subgroups were defined according to the recurrence type (locoregional vs...
October 5, 2016: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
https://www.readbyqxmd.com/read/27703114/sex-and-gender-differences-in-gastroesophageal-reflux-disease
#12
Young Sun Kim, Nayoung Kim, Gwang Ha Kim
It is important to understand sex and gender-related differences in gastroesophageal reflux disease (GERD) because gender-related biologic factors might lead to better prevention and therapy. Non-erosive reflux disease (NERD) affects more women than men. GERD symptoms are more frequent in patients with NERD than in those with reflux esophagitis. However, men suffer pathologic diseases such as reflux esophagitis, Barrett's esophagus (BE), and esophageal adenocarcinoma (EAC) more frequently than women. The prevalence of reflux esophagitis is significantly increased with age in women, especially after their 50s...
October 30, 2016: Journal of Neurogastroenterology and Motility
https://www.readbyqxmd.com/read/27697984/multimodality-therapy-of-localized-gastric-adenocarcinoma
#13
REVIEW
Brian Badgwell
Surgical resection is the primary method of obtaining a potential cure for patients with gastric adenocarcinoma. However, chemotherapy or chemoradiotherapy offer significant improvement in survival over surgery alone. Much of the difficulty in deciding the optimal treatment strategy is choosing between perioperative chemotherapy or adjuvant chemoradiotherapy. Adding to the complexity is the potential for incorporating treatment strategies based on clinical trials performed in Asia. There is likely a difference in tumor biology between Eastern and Western patients with gastric adenocarcinoma, in addition to the clear differences in screening, pathologic assessment, and surgical technique...
October 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27677565/improved-functional-results-after-minimally-invasive-esophagectomy-intrathoracic-versus-cervical-anastomosis
#14
Frans van Workum, Jolijn van der Maas, Frits J H van den Wildenberg, Fatih Polat, Ewout A Kouwenhoven, Marc J van Det, Grard A P Nieuwenhuijzen, Misha D Luyer, Camiel Rosman
BACKGROUND: Both cervical esophagogastric anastomosis (CEA) and intrathoracic esophagogastric anastomosis (IEA) are used to restore gastrointestinal integrity following minimally invasive esophagectomy (MIE). No prospective randomized data on functional outcome, postoperative morbidity, and mortality between these techniques are currently available. METHODS: A comparison was conducted including all consecutive patients with esophageal carcinoma of the distal esophagus or gastroesophageal junction undergoing MIE with CEA or MIE with IEA from October 2009 to July 2014 in 3 high-volume esophageal cancer centers...
September 24, 2016: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/27675974/real-time-magnetic-resonance-imaging-guided-radiation-therapy-for-gastroesophageal-junction-gastric-cancers
#15
S A Rosenberg, A P Wojcieszynski, C R Hullett, M W Geurts, J Bayouth, P M Harari, M Bassetti
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27674041/sequence-of-radiation-therapy-versus-surgery-on-outcomes-in-gastroesophageal-junction-cancer
#16
S K Kim, C Oromendia, P Christos, A G Wernicke, B Parashar
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27641320/no-survival-difference-with-neoadjuvant-chemoradiotherapy-compared-with-chemotherapy-in-resectable-esophageal-and-gastroesophageal-junction-adenocarcinoma-results%C3%A2-from-the-national-cancer-data-base
#17
Eisar Al-Sukhni, Emmanuel Gabriel, Kristopher Attwood, Moshim Kukar, Steven J Nurkin, Steven N Hochwald
BACKGROUND: Neoadjuvant treatment improves survival in resectable esophageal adenocarcinoma, but the optimal regimen has not been defined. Neoadjuvant chemoradiation (nCRT) is associated with higher pathologic complete response (pCR) relative to chemotherapy (nCTX), but has not been shown to improve survival; however, previous studies have been underpowered to demonstrate a survival difference. The objective of this study was to determine if nCRT is associated with increased survival relative to nCTX in patients with resectable esophageal adenocarcinoma...
December 2016: Journal of the American College of Surgeons
https://www.readbyqxmd.com/read/27636304/an-update-in-the-nonendoscopic-treatment-of-gastric-cancer
#18
David H Ilson
PURPOSE OF REVIEW: This article reviews the recent seminal studies in esophagogastric cancer. RECENT FINDINGS: Regular low aspirin use may reduce the risk of esophagogastric cancer. Laparoscopic resection of locally advanced gastric cancer appears equivalent to open resection. There is no survival benefit for the addition of postoperative radiation therapy to adjuvant chemotherapy after primary gastric cancer resection. For tumors of the esophagus and gastroesophageal junction, the combination of preoperative radiation therapy with concurrent chemotherapy may be required to ensure achievement of a negative surgical margin and to reduce local tumor recurrence...
November 2016: Current Opinion in Gastroenterology
https://www.readbyqxmd.com/read/27635275/management-and-reconstruction-of-a-gastroesophageal-junction-adenocarcinoma-patient-three-years-after-pancreaticoduodenectomy-a-surgical-puzzle
#19
Dionysios Dellaportas, James A Gossage, Andrew R Davies
Introduction. With the improving survival of cancer patients, the development of a secondary primary cancer is an increasingly common phenomenon. Extensive surgery during initial treatment may pose significant challenges to surgeons managing the second primary cancer. Case Presentation. A 69-year-old male, who had a pancreaticoduodenectomy three years ago for pancreatic head adenocarcinoma, underwent an uneventful extended total gastrectomy for gastroesophageal junctional adenocarcinoma. The reconstruction controversies and considerations are highlighted...
2016: Case Reports in Surgery
https://www.readbyqxmd.com/read/27623234/biomarker-analyses-in-regard-gastric-gej-carcinoma-patients-treated-with-vegfr2-targeted-antibody-ramucirumab
#20
Charles S Fuchs, Josep Tabernero, Jiří Tomášek, Ian Chau, Bohuslav Melichar, Howard Safran, Mustapha A Tehfe, Dumitru Filip, Eldar Topuzov, Luis Schlittler, Anghel Adrian Udrea, William Campbell, Stephen Brincat, Michael Emig, Symantha A Melemed, Rebecca R Hozak, David Ferry, C William Caldwell, Jaffer A Ajani
BACKGROUND: Angiogenesis inhibition is an important strategy for cancer treatment. Ramucirumab, a human IgG1 monoclonal antibody that targets VEGF receptor 2 (VEGFR2), inhibits VEGF-A, -C, -D binding and endothelial cell proliferation. To attempt to identify prognostic and predictive biomarkers, retrospective analyses were used to assess tumour (HER2, VEGFR2) and serum (VEGF-C and -D, and soluble (s) VEGFR1 and 3) biomarkers in phase 3 REGARD patients with metastatic gastric/gastroesophageal junction carcinoma...
October 11, 2016: British Journal of Cancer
keyword
keyword
110187
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"